The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Subscribe To Our Newsletter & Stay Updated
